$CHRS News
Last published 1d ago
- 1d agoCHRSGuggenheim 3rd Annual Healthcare Innovation Conference - COHERUS ONCOLOGY INCEarnings Call TranscriptsAll right, so welcome to the first session of the second day of the Guggenheim conference. My name is Paul Jang. I'm a biotech analyst with Gugkenheim, and I'm very pleased to welcome our first company of the day to kick
- 2d agoCHRSCoherus Oncology, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2d agoCHRSCoherus Oncology Reports Third Quarter 2026 Financial Results and Announces Strategic Prioritization PlanGlobeNewswire– Focus development efforts on tagmokitug/toripalimab as a potential best-in-disease treatment for esophageal cancer with plans for expedited development – – Deprioritize development of tagmokitug/toripalimab in other
- 2d agoCHRSCoherus Oncology Reports Third Quarter 2026 Financial Results and Announces Strategic Prioritization PlanGlobeNewswire– Focus development efforts on tagmokitug/toripalimab as a potential best-in-disease treatment for esophageal cancer with plans for expedited development –
- 2d agoCHRSQ3 2026 Coherus Oncology, Inc. Earnings Conference Call - COHERUS ONCOLOGY INCEarnings Call TranscriptsGood day and thank you for standing by. Welcome to the Q3 2026 Coherence Oncology Inc. Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a
- 2w agoCHRSINTERIM TAGMOKITUG CLINICAL DATA – WEBCAST - COHERUS ONCOLOGY INCEarnings Call TranscriptsGood day and thank you for standing by. Welcome to the interim Tagmo Kika clinical data webcast. At this time all participants are in a listen only mode. After the speaker's presentation there will be a question and answ
- 2w agoCHRSCoherus Oncology Announces Compelling Tagmokitug Interim Clinical Data in Esophageal Cancer and Path to Advance DevelopmentGlobeNewswire-1L ESCC confirmed ORR of 75% irrespective of PD-L1 status, confirmed ORR of 100% for PD-L1- positive, in evaluable patients- -2L ESCC durable clinical benefit observed with a clear dose-response irrespective of PD-L1
- 2w agoCHRSCoherus to Participate in Upcoming Investor ConferencesGlobeNewswireREDWOOD CITY, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today announced that the company will be webcasting its participation in the following upcoming investor conferences:
- 2w agoCHRSCoherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026GlobeNewswireREDWOOD CITY, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today announced that its third quarter 2026 financial results will be released on Monday, November 9, 2026. Starting at
- 4w agoCHRSCoherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026GlobeNewswireREDWOOD CITY, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS) today announced that the Company will release interim clinical data related to its tagmokitug development program evaluating
- 1mo agoCHRSCoherus Oncology, Inc. - 1773736 - COHERUS ONCOLOGY INCEarnings Call TranscriptsGood afternoon, everybody. Thanks for joining us here for the next session. Really pleased to have Coheris with us. I'm going to turn it over to Danny to make some opening comments, and then we can jump into Q&A. Thank y
- 1mo agoCHRSMorgan Stanley 24th Annual Global Healthcare Conference - COHERUS ONCOLOGY INCEarnings Call TranscriptsGood afternoon, everybody. Thanks for joining us here for the next session. Really pleased to have Coheris with us. I'm going to turn it over to Danny to make some opening comments, and then we can jump into Q&A. Thank y
- 1mo agoCHRSBAIRD 2026 GLOBAL HEALTHCARE CONFERENCE - COHERUS ONCOLOGY INCEarnings Call TranscriptsWelcome to the Bayard Health Care Conference. Really excited to get things kicked off today with Coherus Oncology. The management team here to my left are going to do a presentation, and looking forward to hearing the ex
- 1mo agoCHRSBAIRD 2026 GLOBAL HEALTHCARE CONFERENCE - COHERUS ONCOLOGY INCEarnings Call TranscriptsWelcome to the Bayard Health Care Conference. Really excited to get things kicked off today with Coherus Oncology. The management team here to my left are going to do a presentation, and looking forward to hearing the ex
- 2mo agoCHRSCoherus to Participate in Upcoming Investor ConferencesGlobeNewswireREDWOOD CITY, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today announced that the company will be participating in upcoming investor conferences: Baird 2026 Global
- 2mo agoCHRSCoherus Oncology Announces Special Dividend of Biosimilar Contingent Value RightsGlobeNewswire– Entitles holders to receive net proceeds from sale of remaining Legacy Biosimilar Assets – – Completes transformation of Coherus Oncology into a fully integrated, innovative immuno-oncology company – REDWOOD CITY,
- 3mo agoCHRSCoherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire– LOQTORZI® net revenue of $13.6 million in Q2 2026, up 15% over Q1 – – Clinical data continue to mature across programs with emerging evidence of activity with tagmokitug in head and neck cancer – – Projected October
- 3mo agoCHRSCoherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026GlobeNewswireREDWOOD CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today announced that its second quarter 2026 financial results will be released on Wednesday, August 5, 2026. Starting at
- 4mo agoCHRSCoherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)GlobeNewswireREDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS) and Zumutor Biologics Inc. ("Zumutor"), an immuno-oncology biotech company, today announced a clinical collaboration
- 6mo agoGTBPARTVFATEIBRX+1Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth PhasePR NewswireMomentum around solid tumor cancer treatments is picking up fast as new technologies and therapies continue delivering encouraging results across...
- 6mo agoCHRSQ1 2026 Coherus Oncology, Inc. Earnings Conference CallCOHERUS ONCOLOGY INCEarnings Call TranscriptsGood day and thank you for standing by. Welcome to the Q1 2026 Coherus Oncology Inc. Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a q
- 6mo agoCHRSCoherus Oncology Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire– LOQTORZI® net revenue of $11.8 million in Q1 2026 – – Patient accrual complete for 1L HCC Phase 2 randomized clinical trial for anti-IL27 casdozokitug, timing for data readouts tracking to projections – –
- 6mo agoCHRSCoherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026GlobeNewswireREDWOOD CITY, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today announced that its first quarter 2026 financial results will be released after market close on Monday, May 11, 2026.
- 8mo agoCHRSCoherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswire– LOQTORZI® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 – – Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 – – $172.1 million in
- 8mo agoCHRSCoherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026GlobeNewswireREDWOOD CITY, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today announced that its full year and fourth quarter 2025 financial results will be released after market close on Monday,
- 8mo agoCHRSCoherus Oncology to Participate in Upcoming Investor ConferencesGlobeNewswireREDWOOD CITY, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS) today announced that senior management will be presenting during upcoming conferences. The presentations will be accessible
- 8mo agoCHRSCoherus Oncology, Inc. Announces Closing of Public Offering of Common StockGlobeNewswire–The Offering was led by healthcare-dedicated investors including Janus Henderson Investors, HBM Healthcare Investments and Samsara BioCapital– REDWOOD CITY, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology,
- 9mo agoCHRSCoherus Oncology, Inc. Announces Pricing of Public Offering of Common StockGlobeNewswireREDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. ("Coherus" or the "Company") (NASDAQ:CHRS), today announced the pricing of an underwritten public offering of 28,600,000 shares of the
- 9mo agoCHRSCoherus Oncology, Inc. Announces Proposed Public Offering of Common StockGlobeNewswireREDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. ("Coherus" or the "Company") (NASDAQ:CHRS), today announced a proposed underwritten public offering of its common stock (the "Offering").
- 9mo agoONCYMRNAMRKVIR+1Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer BenchmarksPR NewswireEquity-Insider.com News Commentary – The global oncology therapy market is charging toward a massive $668 billion valuation by 2034, as a ruthless...
- 9mo agoGTBPIBRXERASCHRS+1Functional Force: Precision Platforms Disrupt the 2026 Tumor LandscapePR NewswireEquity Insider News Commentary – The precision medicine sector is undergoing a structural realignment toward platform-based biologics, as the market...
- 10mo agoALLOCHRSELVNONCY+1The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent CliffGlobeNewswireVANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The biotechnology sector is entering a high-stakes survival sprint as major pharmaceutical giants confront a looming
- 10mo agoCHRSCoherus Management to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireREDWOOD CITY, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS) today announced that senior management will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January
- 10mo agoCHRSCoherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)GlobeNewswire-Coherus Oncology formally introduces non-proprietary name: tagmokitug- -Publication shows picomolar affinity for CCR8 with no off-target binding and proof-of- mechanism in preclinical and clinical studies- -Data show
- 11mo agoCHRSCoherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal CarcinomaGlobeNewswireREDWOOD CITY, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS) today announced compelling six-year overall survival (OS) follow-up results from the Phase 3 JUPITER-02 trial evaluating
- 1y agoCHRSCoherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic AntibodyGlobeNewswire– CHS-114 demonstrated robust and selective depletion of CCR8+ Tregs as well as favorable immune remodeling in tumor tissue from head and neck squamous cell carcinoma (HNSCC) patients – – CHS-114 administration resulted
- 1y agoCHRSCoherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswire– CHS-114, a highly selective Treg depleter, clinical program expanded to include colorectal cancer – – Q3 2025 ending cash, cash equivalents and marketable securities of $191.7 million – – LOQTORZI® net revenue
- 1y agoCHRSArvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs OfficerGlobeNewswire– Responsible for Corporate Development, Investor Relations, Government Affairs – REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today announced that Arvind Sood has
- 1y agoCHRSCoherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025GlobeNewswireREDWOOD CITY, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today announced that its third quarter 2025 financial results will be released after market close on Thursday, November 6,
- 1y agoCHRSCoherus Oncology to Participate in Upcoming Investor ConferencesGlobeNewswireREDWOOD CITY, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS) today announced that the company will be webcasting its presentations at the following upcoming conferences: UBS Global
- 1y agoCHRSCoherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)GlobeNewswireREDWOOD CITY, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today announced an upcoming poster presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
- 1y agoCHRSCoherus Oncology to Participate in Upcoming Investor ConferencesGlobeNewswireREDWOOD CITY, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS) today announced that the company will be webcasting its participation in the following upcoming conferences: Baird 2025
- 1y agoCHRSCoherus Oncology, Inc. (CHRS) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoCHRSCoherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswire– LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 – – Data readouts for CHS-114 and casdozokitug on track for 1H 2026 – – Q2 2025 ending cash, cash equivalents and marketable securities of
- 1y agoCHRSCoherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025GlobeNewswireREDWOOD CITY, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. ((Coherus, Coherus Oncology or the Company, NASDAQ:CHRS), today announced that its second quarter 2025 financial results will be released
- 1y agoCHRSCoherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer TherapeuticsGlobeNewswireREDWOOD CITY, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. ((Coherus Oncology, NASDAQ:CHRS), a commercial-stage innovative oncology company, formerly named Coherus BioSciences Inc., announced its
- 1y agoCHRSCoherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi)GlobeNewswireREDWOOD CITY, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS), today announced a clinical collaboration with STORM Therapeutics, Ltd. ("STORM") to evaluate STC-15, a METTL3
- 1y agoCHRSCoherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswire– Strategic transformation to innovative oncology completed in Q2 2025 – – Positive CHS-114 (anti-CCR8 antibody) Phase 1b dose expansion study data in patients with head and neck cancer presented at 2025 AACR Annual
- 1y agoCHRSCoherus to Report First Quarter 2025 Financial Results on May 12, 2025GlobeNewswireREDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS) today announced that its first quarter 2025 financial results will be released after market close on Monday, May
- 1y agoCHRSCoherus to Participate in Upcoming Investor ConferencesGlobeNewswireREDWOOD CITY, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS) today announced that the company will be webcasting its participation in the upcoming conferences: Citizens